Total amount raised
$442M
Latest funding date
2026-01-09
Location
Orca Bio has successfully raised funding over five rounds, with the latest being a Series F round led by Lightspeed Venture Partners. The company is backed by a total of 13 investors, including Silicon Valley Bank.
What Is Orca Bio?
Orca Bio, based in Menlo Park, California, is a clinical-stage cell therapy company dedicated to delivering curative medicine to patients. The company operates within the health care, medical, and pharmaceutical industries and has an employee count ranging from 251 to 500.
Focused on developing high-precision cell therapies for cancer and autoimmune diseases, Orca Bio leverages regulatory T cells to improve patient outcomes. The company is committed to expanding the life-changing benefits of cell therapies, ensuring that all patients have a chance at a cure.
How Much Funding Has Orca Bio Raised?
- Series F
- Amount Raised: Part of $250M aggregate across Series E and Series F combined (amounts per round broadly comparable, each approximately $125M; individual round amounts not formally disclosed)
- Date: December 2025 (closed; announced January 9, 2026)
- Lead Investors: Lightspeed Venture Partners
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To support launch readiness ahead of the Orca-T PDUFA date and drive potential commercialization of Orca Bio's lead cell therapy.
- Series E
- Amount Raised: Part of $250M aggregate across Series E and Series F combined (amounts per round broadly comparable; individual round amounts not formally disclosed)
- Date: 2024 (previously undisclosed at time of completion)
- Lead Investors: Undisclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To advance clinical programs and support ongoing pipeline development ahead of regulatory milestones.
- Series D
- Amount Raised: USD 192,000,000
- Date: June 17, 2020
- Lead Investors: Lightspeed Venture Partners (co-led with an undisclosed investor)
- Other Investors: 8VC, DCVC Bio, ND Capital, Mubadala Investment Company, Kaiser Foundation Hospitals, Kaiser Permanente Group Trust, IMRF
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To develop Orca Bio's pipeline of cell therapies and its manufacturing technology, aiming to replace conventional bone marrow transplants.
- Earlier Rounds (Pre-Seed, Series A, Series B, Series C)
- Combined Amount Raised: Approximately USD 108,000,000 (implied; individual round amounts not publicly disclosed)
- Dates: 2016–2020 (Pre-Seed: May 2016; Series A: 2017; Series B: 2019; Series C: 2018–2020)
- Lead Investors: Undisclosed per individual round
- Valuation at Rounds: Not publicly disclosed
- Motivation Behind the Rounds: To establish initial operations, begin early-stage research, advance clinical trials, and expand research capabilities.
Total Amount Raised: At least $442M based on disclosed and implied funding (USD 192M Series D + ~USD 108M in earlier rounds + USD 250M aggregate across Series E and Series F). Note: Individual Series E and Series F amounts were described as broadly comparable but not individually disclosed by the company.
Current Valuation: Not publicly disclosed
Key Investors
- Lightspeed Venture Partners
- Details: Lightspeed Venture Partners is a venture capital firm that invests in the enterprise, consumer, and health sectors. They have a global presence and have backed numerous successful startups. Lightspeed co-led the Series D and led the Series F for Orca Bio.
- Investment Focus Areas: Technology, enterprise, consumer, health sectors
- Notable Investments: Snapchat, GrubHub, Affirm
- 8VC
- Details: 8VC is a venture capital firm that focuses on technology and healthcare investments. They participated in Orca Bio's Series D round.
- Investment Focus Areas: Technology, healthcare, logistics, financial services
- Notable Investments: Palantir, Wish, Guardant Health
- DCVC Bio
- Details: DCVC Bio is a venture capital firm specializing in deep tech and life sciences. They participated in Orca Bio's Series D round.
- Investment Focus Areas: Deep tech, life sciences, computational biology
- Notable Investments: Zymergen, Recursion Pharmaceuticals, Pivot Bio
- ND Capital
- Details: ND Capital is a venture capital firm that invests in early-stage technology and life sciences companies. They participated in Orca Bio's Series D round.
- Investment Focus Areas: Life sciences, technology, sustainability
- Notable Investments: Impossible Foods, Ginkgo Bioworks, Unity Biotechnology
- Mubadala Investment Company
- Details: Mubadala Investment Company is a global investment firm based in Abu Dhabi that participated in Orca Bio's Series D round.
- Investment Focus Areas: Technology, healthcare, infrastructure
- Notable Investments: SoftBank Vision Fund, Cologix, Medallia
What's Next for Orca Bio?
Orca Bio stands at the forefront of a transformative opportunity in the healthcare sector. With its focus on developing high-precision cell therapies, the company aims to replace conventional bone marrow transplants, addressing significant unmet needs in treating blood cancers, autoimmune diseases, and genetic disorders. The potential to mitigate severe complications like graft-versus-host disease makes their therapies highly attractive, promising a substantial market impact.
As Orca Bio advances its clinical programs, including TRGFT-201 and OGFT-001, the company is well-positioned for future fundraising opportunities. Successful trial outcomes could attract further investment, potentially leading to additional funding rounds or strategic partnerships. The growing interest in precision medicine and cell therapies aligns with Orca Bio's mission, enhancing its appeal to investors and partners alike.
However, the path forward is not without challenges. Regulatory hurdles, clinical trial risks, and competition from other biotech firms are significant obstacles. Additionally, the high costs associated with developing and manufacturing cell therapies could pose financial strains. Despite these challenges, Orca Bio's innovative approach and strong investor backing provide a solid foundation for future growth and success.
Use Clay to Get Funding Data
Sales professionals, leverage Clay's platform to access comprehensive fundraising data on companies like Orca Bio and gather other critical business insights. Sign up for free to start transforming your sales strategy today.
